Stemline Therapeutics, Inc.: ELZONRIS, targeted therapy directed to IL-3 receptor (CD123, approved for BPDC; SL-801 an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial; and SL-701 an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Marketed, Phase l or ll
Disease Space
Immunotherapy, Oncology, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
750 Lexington Ave
11th Floor
New York, NY 10022
United States

Company Participants at Stemline Therapeutics KOL Event at ASH 2018

  • Ivan Bergstein, M.D., Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access Event

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.